RANI Rani Therapeutics Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1856725 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY448.7%
TTM net income YoY-14.6%
TTM EPS YoY90.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-530.5%
Net margin-493.0%
FCF margin-352.7%
EBITDA margin-520.6%
Returns
ROE-248.6%
ROA-103.6%
ROIC (approx.)-173.1%
Asset turnover0.21x
Leverage & solvency
Liabilities / assets21.3%
Debt / equity0.00x
Current ratio5.26x
Interest coverage-71.86x
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-30.2%
Payout ratio—
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.71M | $1.71M | $1.71M | $1.46M | $0 | $0 | $172,000 | $1.03M |
| R&D expense | $6.02M | $5.02M | $5.16M | $4.91M | $3.22M | $5.50M | $6.57M | $6.81M |
| SG&A expense | $4.91M | $5.52M | $4.89M | $5.09M | $4.04M | $5.00M | $5.62M | $5.46M |
| Operating income | -$9.22M | -$8.83M | -$8.34M | -$8.54M | -$7.26M | -$10.51M | -$12.01M | -$14.96M |
| Interest expense | $43,000 | $8,000 | $88,000 | $347,000 | $725,000 | $877,000 | $943,000 | $1.12M |
| Net income | -$7.73M | -$7.39M | -$7.03M | -$10.30M | -$5.41M | -$6.69M | -$7.26M | -$8.95M |
| EBITDA | -$9.12M | -$8.63M | -$8.18M | -$8.35M | -$7.06M | -$10.30M | -$11.76M | -$14.69M |
| EPS (basic) | -0.04 | -0.04 | -0.04 | — | -0.12 | -0.18 | -0.22 | — |
| EPS (diluted) | -0.04 | -0.04 | -0.04 | — | -0.12 | -0.18 | -0.22 | — |
| Weighted avg. shares (diluted) | 199.01M | 187.17M | 180.00M | — | 46.44M | 36.54M | 33.44M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.62M | $4.87M | $9.64M | $18.62M | $4.14M | $10.22M | $10.11M | $4.26M |
| Receivables | $1.96M | $2.04M | $2.04M | $2.04M | — | — | $600,000 | $0 |
| Current assets | $48.48M | $56.52M | $47.09M | $53.32M | $4.96M | $11.07M | $17.78M | $29.74M |
| PP&E, net | $659,000 | $525,000 | $601,000 | $736,000 | $922,000 | $1.14M | $1.35M | $1.55M |
| Total assets | $52.53M | $60.84M | $51.88M | $58.62M | $10.14M | $16.90M | $24.12M | $36.63M |
| Current liabilities | $9.22M | $10.64M | $13.86M | $12.67M | $19.14M | $20.62M | $20.13M | $19.89M |
| Short-term debt | — | — | — | $0 | $13.54M | $15.00M | $15.00M | $15.00M |
| Long-term debt | — | — | — | $0 | $0 | $2.23M | $5.92M | $9.61M |
| Total debt | — | — | — | $0 | $13.54M | $17.23M | $20.92M | $24.61M |
| Total liabilities | $11.18M | $12.86M | $16.34M | $17.11M | $22.11M | $26.05M | $29.47M | $33.14M |
| Shareholders' equity | $33.97M | $39.23M | $28.41M | $33.01M | -$7.86M | -$5.58M | -$3.06M | $1.99M |
| Net debt | — | — | — | -$18.62M | $9.39M | $7.01M | $10.81M | $20.35M |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.76M | -$9.03M | -$6.50M | $294,000 | -$5.06M | -$5.80M | -$8.15M | -$8.65M |
| Capital expenditure | $183,000 | $32,000 | $15,000 | $0 | $0 | $37,000 | $51,000 | $31,000 |
| Free cash flow | -$7.94M | -$9.06M | -$6.51M | $294,000 | -$5.06M | -$5.83M | -$8.20M | -$8.69M |
| Investing cash flow | $6.86M | -$14.56M | -$2.45M | -$30.97M | $0 | $5.71M | $18.23M | $2.52M |
| Financing cash flow | -$347,000 | $18.81M | -$27,000 | $44.85M | -$1.01M | $188,000 | -$3.73M | $5.62M |
| Depreciation & amortization | $100,000 | $200,000 | $161,000 | $186,000 | $200,000 | $200,000 | $251,000 | $266,000 |
| Stock-based compensation | $2.21M | $2.42M | $2.08M | $2.24M | $2.34M | $3.29M | $3.92M | $3.99M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.